IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IDEXX LABORATORIES INC /DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$555.80−4.56 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $44.08B
- P/E (TTM)
- 39.1
- Dividend yield
- –
IDEXX LABORATORIES INC /DE revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG segment revenue | $4.18B | $4.09B | $3.95B | $3.83B | $3.70B | $3.60B | $3.57B | $3.52B | $3.47B | $3.41B | $3.35B | $3.28B | 91.9% | +12.9% |
| Water segment revenue | $213.66M | $206.09M | $201.15M | $195.77M | $191.64M | $187.36M | $185.11M | $181.75M | $176.03M | $172.34M | $168.15M | $165.68M | 4.7% | +11.5% |
| LPD | $139.09M | $135.67M | $131.79M | $128.86M | $123.91M | $122.45M | $122.06M | $120.30M | $121.05M | $120.66M | $121.66M | $122.26M | 3.1% | +12.3% |
| Other segment revenue | – | – | – | – | – | – | – | $17.94M | $17.71M | $17.50M | $18.79M | $20.36M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG segment revenue | – | – | – | – | – | – | – | $1.02B | $996.73M | $1.03B | $1.01B | $990.46M | – |
| Water segment revenue | – | – | – | – | – | – | – | $80.76M | $77.48M | $76.80M | $74.34M | $75.14M | – |
| LPD | – | – | – | – | – | – | – | $7.57M | $9.08M | $9.53M | $9.98M | $11.03M | – |
| Other segment revenue | – | – | – | – | – | – | – | $3.17M | $53.00K | -$1.33M | $73.00K | $1.73M | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $2.69B | $2.63B | $2.54B | $2.45B | $2.36B | $2.28B | $2.25B | $2.21B | $2.16B | $2.13B | $2.09B | $2.04B | 59.2% | +14.2% |
| Service revenue | $1.86B | $1.81B | $1.76B | $1.72B | $1.68B | $1.65B | $1.65B | $1.63B | $1.62B | $1.60B | $1.57B | $1.54B | 40.8% | +10.8% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.88B | $2.82B | $2.75B | $2.68B | $2.61B | $2.56B | $2.53B | $2.51B | $2.47B | $2.43B | $2.39B | $2.35B | 63.2% | +10.1% |
| Europe, the Middle East and Africa | $1.02B | $989.76M | $937.25M | $890.49M | $844.03M | $811.45M | $806.73M | $782.78M | $762.03M | $740.01M | $716.18M | $691.52M | 22.4% | +21.1% |
| Asia Pacific | $380.78M | $368.58M | $355.93M | $345.07M | $335.32M | $326.45M | $321.02M | $320.09M | $316.78M | $317.25M | $319.31M | $315.73M | 8.4% | +13.6% |
| Canada | $175.06M | $170.97M | $167.33M | $163.62M | $159.17M | $153.47M | $152.89M | $151.53M | $150.22M | $150.86M | $150.11M | $147.55M | 3.8% | +10.0% |
From the segment and revenue-disaggregation notes of Idexx Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.